- Home
- CWEN vs TVTX Comparison
CWEN vs TVTX Comparison
Compare CWEN & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CWEN | TVTX |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.3B |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | CWEN | TVTX |
|---|---|---|
| Price | $33.94 | $39.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 15 |
| Target Price | ★ $39.25 | $37.21 |
| AVG Volume (30 Days) | 910.3K | ★ 1.7M |
| Earning Date | 11-04-2025 | 02-19-2026 |
| Dividend Yield | ★ 5.32% | N/A |
| EPS Growth | ★ 125.75 | N/A |
| EPS | ★ 2.34 | N/A |
| Revenue | ★ $1,375,000,000.00 | $435,826,000.00 |
| Revenue This Year | $4.08 | $120.02 |
| Revenue Next Year | $14.02 | $37.00 |
| P/E Ratio | $14.22 | ★ N/A |
| Revenue Growth | 0.81 | ★ 114.22 |
| 52 Week Low | $24.40 | $12.91 |
| 52 Week High | $36.89 | $42.13 |
Technical Indicators
Market Signals| Indicator | CWEN | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.00 | 62.15 |
| Support Level | $33.20 | $37.23 |
| Resistance Level | $33.69 | $42.13 |
| Average True Range (ATR) | 0.61 | 1.97 |
| MACD | 0.10 | 0.25 |
| Stochastic Oscillator | 91.51 | 67.65 |
Price Performance
Historical ComparisonAbout CWEN Clearway Energy Inc. Class C
Clearway Energy Inc is a publicly-traded energy infrastructure investor with a focus on investments in clean energy and owner of modern, sustainable and long-term contracted assets across North America. The company segments its operations into Flexible Generation, renewables and Corporate divisions.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.